https://www.taxtmi.com/highlights?id=85445 Under Customs Act s.25(1), MoF amended notification 16/2017-Customs to expand customs duty exemptions for specified pharmaceutical drugs distributed through Patient Assistance Programs (PAPs). The amendment adds 37 new pharmaceutical products (entries 53-89) from multiple manufacturers including MSD Pharmaceuticals, Pfizer, Novartis, AstraZeneca, Johnson & Johnson, Merck, Takeda, GSK, and Roche. The exempted drugs include treatments for cancer, rare diseases, and autoimmune conditions. The notification takes effect from February 2, 2025, demonstrating government's commitment to improve access to specialized medications through manufacturer-sponsored patient support programs. en-us Sun, 02 Feb 2025 10:16:59 +0530 Sun, 02 Feb 2025 10:16:59 +0530 TaxTMI RSS Generator https://www.taxtmi.com/highlights?id=85445 Under Customs Act s.25(1), MoF amended notification 16/2017-Customs to expand customs duty exemptions for specified pharmaceutical drugs distributed through Patient Assistance Programs (PAPs). The amendment adds 37 new pharmaceutical products (entries 53-89) from multiple manufacturers including MSD Pharmaceuticals, Pfizer, Novartis, AstraZeneca, Johnson & Johnson, Merck, Takeda, GSK, and Roche. The exempted drugs include treatments for cancer, rare diseases, and autoimmune conditions. The notification takes effect from February 2, 2025, demonstrating government's commitment to improve access to specialized medications through manufacturer-sponsored patient support programs. Highlights Customs Sun, 02 Feb 2025 10:16:59 +0530 https://www.taxtmi.com/highlights?id=85445